<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03987191</url>
  </required_header>
  <id_info>
    <org_study_id>19-0924</org_study_id>
    <nct_id>NCT03987191</nct_id>
  </id_info>
  <brief_title>Insulin Pump to Multiple Daily Injection Transition Clinical Trial</brief_title>
  <acronym>TRANSITION</acronym>
  <official_title>Successful Transition From Insulin Pump to Multiple Daily Injections Using Insulin Degludec in Adults With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled, two arms, investigator initiated, intervention study is aimed to&#xD;
      examine an investigational approach in contrast to the clinical standard of 1:1 dose basal&#xD;
      insulin conversion in an attempt to lower the incidence and/or duration of hyperglycemia&#xD;
      after transition from insulin pump to multiple daily injections in adults with type 1&#xD;
      diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Second generation long acting insulin, insulin degludec, has been shown to improve glycemic&#xD;
      control and reduce hypoglycemia in patients with type 1 diabetes and insulin treated type 2&#xD;
      diabetes. However, it takes about 48 hours before glycemic benefits are noticeable.&#xD;
      Therefore, transition from insulin pump to multiple daily injection using insulin degludec is&#xD;
      associated with hyperglycemia during first 48 hours of transition. Considering this, this&#xD;
      study proposes to evaluate an investigational strategy to improve glycemic control during&#xD;
      transition from insulin pump to multiple daily injections using insulin degludec and insulin&#xD;
      aspart.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2020</start_date>
  <completion_date type="Actual">October 8, 2020</completion_date>
  <primary_completion_date type="Actual">October 8, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time Spent With CGM Glucose Levels &gt;180mg/dl Between Two Groups</measure>
    <time_frame>7 days from the randomization</time_frame>
    <description>The primary outcome will be time spent in CGM glucose &gt;180 mg/dL (hyperglycemia) during 7days of randomization period between two groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time Spent in CGM-measured &quot;Time-in-range&quot;(Glucose Levels ≥70 mg /dl and ≤180 mg/dl) Between Two Groups</measure>
    <time_frame>7 days from the randomization</time_frame>
    <description>CGM TIR between two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent in CGM-measured Hypoglycemia &lt; 70 mg/dl Between Two Groups</measure>
    <time_frame>7 days from the randomization</time_frame>
    <description>CGM time below 70 between two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Severe Hypoglycemia as Defined by the ADA (Severe Cognitive Impairment Requiring External Assistance for Recovery) and Severe Hyperglycemia (BG≥250 Needing Hospitalization) Between Two Groups</measure>
    <time_frame>7 days from the randomization</time_frame>
    <description>Frequency of SH and DKA between two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Boluses (Correction Boluses) Between Groups During First 72 Hours of Randomization</measure>
    <time_frame>72 hours from the randomization</time_frame>
    <description>no of correction boluses between two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Delivery Satisfaction (IDSS Survey) Between Two Groups</measure>
    <time_frame>7 days from the randomization</time_frame>
    <description>PRO between two groups. The Insulin delivery satisfaction survey (IDSS) measures diabetes patients' satisfaction with their insulin delivery system. Possible scores range from 1-5, with higher scores indicating higher satisfaction and a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Activity Impairment (WPAI:SHP Version 2 Questionnaire) Between Two Groups</measure>
    <time_frame>7 days from the randomization</time_frame>
    <description>PRO between two groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Standard of Care Transition</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stopping of insulin pump on the day of randomization and starting insulin degludec in 1:1 ratio (same units as total basal insulin on pump) and insulin Aspart for meals and corrections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inverstigational Transition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of insulin degludec in 1:1 ratio (same units as total basal insulin on pump) on the day of randomization AND concomitant use of the insulin pump for 48 hours from transition, where insulin pump basal rate will be reduced by 50% during the first 24 hours from transition and by 75% during 24 to 48 hours from transition. Insulin pump will be disconnected after 48 hours from transition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multiple daily ijnection using Insulin Degludec and Insulin Aspart</intervention_name>
    <description>Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
    <arm_group_label>Inverstigational Transition</arm_group_label>
    <arm_group_label>Standard of Care Transition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years and ≤ 65 years&#xD;
&#xD;
          2. Patients with T1D diagnosed for at least 12 months&#xD;
&#xD;
          3. Point-of-care HbA1c levels between ≥6.5% and ≤ 8.5%&#xD;
&#xD;
          4. Patients on CSII (any insulin pump) for at least past 6 months&#xD;
&#xD;
          5. Willing and able to wear a blinded CGM during the time of study period&#xD;
&#xD;
          6. Willing to perform self-monitoring of blood glucose (SMBG) at least 4 times a day&#xD;
&#xD;
          7. Ability to provide informed consent before any trial-related activities&#xD;
&#xD;
          8. Not willing to or plan any travel out of Colorado during the 3 weeks of study period&#xD;
&#xD;
          9. Willing to use insulin degludec in the morning once a day&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt;18 years and &gt; 65years&#xD;
&#xD;
          2. HbA1c &gt;8.5 % at screening&#xD;
&#xD;
          3. Less than 12 months of insulin treatment&#xD;
&#xD;
          4. Patients on 670G or Tandem Control IQ (Medtronic and Tandem Hybrid Closed-loop&#xD;
             systems) and not willing use manual mode during the study period&#xD;
&#xD;
          5. Patients with T1D using any glucose lowering medications other than insulin&#xD;
&#xD;
          6. Pregnancy, breast feeding, and positive pregnancy test during screening&#xD;
&#xD;
          7. Women of childbearing age wanting to become pregnant or not using adequate&#xD;
             contraceptive measures&#xD;
&#xD;
          8. Current or recent (&lt; 2 weeks prior to visit 1) use of any steroidal medication, or&#xD;
             anticipated steroidal treatment, during the study period&#xD;
&#xD;
          9. eGFR below 45 ml/min/1.73 m^2 using MDRD formula&#xD;
&#xD;
         10. History of severe hypoglycemia in the previous 3 months&#xD;
&#xD;
         11. History of diabetic ketoacidosis (DKA) requiring hospitalization in the past 3 months&#xD;
&#xD;
         12. History of allergy to any form of insulin or its excipients&#xD;
&#xD;
         13. History of allergy to adhesives&#xD;
&#xD;
         14. Unwilling to use blinded CGM during the study period&#xD;
&#xD;
         15. Unwilling to perform SMPG at least 4 times a day&#xD;
&#xD;
         16. Known history of alcohol abuse or illicit drug use within 6 months prior to screening&#xD;
&#xD;
         17. Use of investigational drugs within 5 half-lives prior to screening&#xD;
&#xD;
         18. Participation to other study trials during the study period&#xD;
&#xD;
         19. Elevated liver enzymes (AST and ALT) 3 times the upper limit of normal&#xD;
&#xD;
         20. Hypoglycemia unawareness defined as GOLD score ≥4 [20]&#xD;
&#xD;
         21. Any comorbidities or medical conditions that make a person unfit for the study at the&#xD;
             discretion of the investigators&#xD;
&#xD;
         22. Anticipated travel across different time zones (difference greater than 4 hours) or&#xD;
             anticipated change in physical activities or diet at the discretion of the&#xD;
             investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Viral Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Davis Center for Diabetes</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>June 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2019</study_first_posted>
  <results_first_submitted>August 11, 2021</results_first_submitted>
  <results_first_submitted_qc>September 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 13, 2021</results_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified academic researchers may request access to de-identified participant level data related to the study. The request letter with details such as reasons for data request, plan for data analysis, publication and so on should be emailed/mailed to the PI of the study (viral.shah@cuanschutz.edu).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>The data will be available after the publication. The data sharing details will be provided in the manuscript.</ipd_time_frame>
    <ipd_access_criteria>The committee (PI, statistician and Sponsor) will decide on appropriate request for data sharing.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 31, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT03987191/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>3 screen failed, 1 participant was lost to follow-up prior to screening, and 2 withdrew from study prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard of Care Transition</title>
          <description>Stopping of insulin pump on the day of randomization and starting insulin degludec in 1:1 ratio (same units as total basal insulin on pump) and insulin Aspart for meals and corrections&#xD;
Multiple daily ijnection using Insulin Degludec and Insulin Aspart: Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
        </group>
        <group group_id="P2">
          <title>Investigational Transition</title>
          <description>Administration of insulin degludec in 1:1 ratio (same units as total basal insulin on pump) on the day of randomization AND concomitant use of the insulin pump for 48 hours from transition, where insulin pump basal rate will be reduced by 50% during the first 24 hours from transition and by 75% during 24 to 48 hours from transition. Insulin pump will be disconnected after 48 hours from transition&#xD;
Multiple daily ijnection using Insulin Degludec and Insulin Aspart: Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Data Collected</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>COVID-19 related research disruption</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No data is available for the two participants who did not have data collected due to COVID-19-related research disruption.</population>
      <group_list>
        <group group_id="B1">
          <title>Standard of Care Transition</title>
          <description>Stopping of insulin pump on the day of randomization and starting insulin degludec in 1:1 ratio (same units as total basal insulin on pump) and insulin Aspart for meals and corrections&#xD;
Multiple daily ijnection using Insulin Degludec and Insulin Aspart: Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
        </group>
        <group group_id="B2">
          <title>Investigational Transition</title>
          <description>Administration of insulin degludec in 1:1 ratio (same units as total basal insulin on pump) on the day of randomization AND concomitant use of the insulin pump for 48 hours from transition, where insulin pump basal rate will be reduced by 50% during the first 24 hours from transition and by 75% during 24 to 48 hours from transition. Insulin pump will be disconnected after 48 hours from transition&#xD;
Multiple daily ijnection using Insulin Degludec and Insulin Aspart: Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.7" spread="9.1"/>
                    <measurement group_id="B2" value="38.2" spread="9.5"/>
                    <measurement group_id="B3" value="36.8" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time Spent With CGM Glucose Levels &gt;180mg/dl Between Two Groups</title>
        <description>The primary outcome will be time spent in CGM glucose &gt;180 mg/dL (hyperglycemia) during 7days of randomization period between two groups.</description>
        <time_frame>7 days from the randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Transition</title>
            <description>Stopping of insulin pump on the day of randomization and starting insulin degludec in 1:1 ratio (same units as total basal insulin on pump) and insulin Aspart for meals and corrections&#xD;
Multiple daily ijnection using Insulin Degludec and Insulin Aspart: Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
          </group>
          <group group_id="O2">
            <title>Investigational Transition</title>
            <description>Administration of insulin degludec in 1:1 ratio (same units as total basal insulin on pump) on the day of randomization AND concomitant use of the insulin pump for 48 hours from transition, where insulin pump basal rate will be reduced by 50% during the first 24 hours from transition and by 75% during 24 to 48 hours from transition. Insulin pump will be disconnected after 48 hours from transition&#xD;
Multiple daily ijnection using Insulin Degludec and Insulin Aspart: Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent With CGM Glucose Levels &gt;180mg/dl Between Two Groups</title>
          <description>The primary outcome will be time spent in CGM glucose &gt;180 mg/dL (hyperglycemia) during 7days of randomization period between two groups.</description>
          <units>percentage of time spent &gt;180 mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.3" lower_limit="43.5" upper_limit="49.1"/>
                    <measurement group_id="O2" value="38.5" lower_limit="30.7" upper_limit="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Spent in CGM-measured &quot;Time-in-range&quot;(Glucose Levels ≥70 mg /dl and ≤180 mg/dl) Between Two Groups</title>
        <description>CGM TIR between two groups</description>
        <time_frame>7 days from the randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Transition</title>
            <description>Stopping of insulin pump on the day of randomization and starting insulin degludec in 1:1 ratio (same units as total basal insulin on pump) and insulin Aspart for meals and corrections&#xD;
Multiple daily ijnection using Insulin Degludec and Insulin Aspart: Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
          </group>
          <group group_id="O2">
            <title>Investigational Transition</title>
            <description>Administration of insulin degludec in 1:1 ratio (same units as total basal insulin on pump) on the day of randomization AND concomitant use of the insulin pump for 48 hours from transition, where insulin pump basal rate will be reduced by 50% during the first 24 hours from transition and by 75% during 24 to 48 hours from transition. Insulin pump will be disconnected after 48 hours from transition&#xD;
Multiple daily ijnection using Insulin Degludec and Insulin Aspart: Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent in CGM-measured &quot;Time-in-range&quot;(Glucose Levels ≥70 mg /dl and ≤180 mg/dl) Between Two Groups</title>
          <description>CGM TIR between two groups</description>
          <units>percentage of time spent in range</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8" lower_limit="44.1" upper_limit="52.1"/>
                    <measurement group_id="O2" value="56.5" lower_limit="51.0" upper_limit="63.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Spent in CGM-measured Hypoglycemia &lt; 70 mg/dl Between Two Groups</title>
        <description>CGM time below 70 between two groups</description>
        <time_frame>7 days from the randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Transition</title>
            <description>Stopping of insulin pump on the day of randomization and starting insulin degludec in 1:1 ratio (same units as total basal insulin on pump) and insulin Aspart for meals and corrections&#xD;
Multiple daily ijnection using Insulin Degludec and Insulin Aspart: Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
          </group>
          <group group_id="O2">
            <title>Investigational Transition</title>
            <description>Administration of insulin degludec in 1:1 ratio (same units as total basal insulin on pump) on the day of randomization AND concomitant use of the insulin pump for 48 hours from transition, where insulin pump basal rate will be reduced by 50% during the first 24 hours from transition and by 75% during 24 to 48 hours from transition. Insulin pump will be disconnected after 48 hours from transition&#xD;
Multiple daily ijnection using Insulin Degludec and Insulin Aspart: Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent in CGM-measured Hypoglycemia &lt; 70 mg/dl Between Two Groups</title>
          <description>CGM time below 70 between two groups</description>
          <units>percentage of time below range</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="2.4" upper_limit="7.2"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.0" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Severe Hypoglycemia as Defined by the ADA (Severe Cognitive Impairment Requiring External Assistance for Recovery) and Severe Hyperglycemia (BG≥250 Needing Hospitalization) Between Two Groups</title>
        <description>Frequency of SH and DKA between two groups</description>
        <time_frame>7 days from the randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Transition</title>
            <description>Stopping of insulin pump on the day of randomization and starting insulin degludec in 1:1 ratio (same units as total basal insulin on pump) and insulin Aspart for meals and corrections&#xD;
Multiple daily ijnection using Insulin Degludec and Insulin Aspart: Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
          </group>
          <group group_id="O2">
            <title>Investigational Transition</title>
            <description>Administration of insulin degludec in 1:1 ratio (same units as total basal insulin on pump) on the day of randomization AND concomitant use of the insulin pump for 48 hours from transition, where insulin pump basal rate will be reduced by 50% during the first 24 hours from transition and by 75% during 24 to 48 hours from transition. Insulin pump will be disconnected after 48 hours from transition&#xD;
Multiple daily ijnection using Insulin Degludec and Insulin Aspart: Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severe Hypoglycemia as Defined by the ADA (Severe Cognitive Impairment Requiring External Assistance for Recovery) and Severe Hyperglycemia (BG≥250 Needing Hospitalization) Between Two Groups</title>
          <description>Frequency of SH and DKA between two groups</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with Severe Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Diabetic Ketoacidosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Boluses (Correction Boluses) Between Groups During First 72 Hours of Randomization</title>
        <description>no of correction boluses between two groups</description>
        <time_frame>72 hours from the randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Transition</title>
            <description>Stopping of insulin pump on the day of randomization and starting insulin degludec in 1:1 ratio (same units as total basal insulin on pump) and insulin Aspart for meals and corrections&#xD;
Multiple daily ijnection using Insulin Degludec and Insulin Aspart: Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
          </group>
          <group group_id="O2">
            <title>Investigational Transition</title>
            <description>Administration of insulin degludec in 1:1 ratio (same units as total basal insulin on pump) on the day of randomization AND concomitant use of the insulin pump for 48 hours from transition, where insulin pump basal rate will be reduced by 50% during the first 24 hours from transition and by 75% during 24 to 48 hours from transition. Insulin pump will be disconnected after 48 hours from transition&#xD;
Multiple daily ijnection using Insulin Degludec and Insulin Aspart: Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Boluses (Correction Boluses) Between Groups During First 72 Hours of Randomization</title>
          <description>no of correction boluses between two groups</description>
          <units>Boluses per day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="4.5" upper_limit="8.7"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3.0" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Delivery Satisfaction (IDSS Survey) Between Two Groups</title>
        <description>PRO between two groups. The Insulin delivery satisfaction survey (IDSS) measures diabetes patients' satisfaction with their insulin delivery system. Possible scores range from 1-5, with higher scores indicating higher satisfaction and a better outcome.</description>
        <time_frame>7 days from the randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Transition</title>
            <description>Stopping of insulin pump on the day of randomization and starting insulin degludec in 1:1 ratio (same units as total basal insulin on pump) and insulin Aspart for meals and corrections&#xD;
Multiple daily ijnection using Insulin Degludec and Insulin Aspart: Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
          </group>
          <group group_id="O2">
            <title>Investigational Transition</title>
            <description>Administration of insulin degludec in 1:1 ratio (same units as total basal insulin on pump) on the day of randomization AND concomitant use of the insulin pump for 48 hours from transition, where insulin pump basal rate will be reduced by 50% during the first 24 hours from transition and by 75% during 24 to 48 hours from transition. Insulin pump will be disconnected after 48 hours from transition&#xD;
Multiple daily ijnection using Insulin Degludec and Insulin Aspart: Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Delivery Satisfaction (IDSS Survey) Between Two Groups</title>
          <description>PRO between two groups. The Insulin delivery satisfaction survey (IDSS) measures diabetes patients' satisfaction with their insulin delivery system. Possible scores range from 1-5, with higher scores indicating higher satisfaction and a better outcome.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="3.9" upper_limit="4.3"/>
                    <measurement group_id="O2" value="3.9" lower_limit="3.8" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Productivity and Activity Impairment (WPAI:SHP Version 2 Questionnaire) Between Two Groups</title>
        <description>PRO between two groups</description>
        <time_frame>7 days from the randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Transition</title>
            <description>Stopping of insulin pump on the day of randomization and starting insulin degludec in 1:1 ratio (same units as total basal insulin on pump) and insulin Aspart for meals and corrections&#xD;
Multiple daily ijnection using Insulin Degludec and Insulin Aspart: Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
          </group>
          <group group_id="O2">
            <title>Investigational Transition</title>
            <description>Administration of insulin degludec in 1:1 ratio (same units as total basal insulin on pump) on the day of randomization AND concomitant use of the insulin pump for 48 hours from transition, where insulin pump basal rate will be reduced by 50% during the first 24 hours from transition and by 75% during 24 to 48 hours from transition. Insulin pump will be disconnected after 48 hours from transition&#xD;
Multiple daily ijnection using Insulin Degludec and Insulin Aspart: Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Work Productivity and Activity Impairment (WPAI:SHP Version 2 Questionnaire) Between Two Groups</title>
          <description>PRO between two groups</description>
          <units>Percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent work time missed due to problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent impairment while working</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.1" upper_limit="0.3"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.1" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent overall work impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent activity impairment due to problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.1" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.2" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard of Care Transition</title>
          <description>Stopping of insulin pump on the day of randomization and starting insulin degludec in 1:1 ratio (same units as total basal insulin on pump) and insulin Aspart for meals and corrections&#xD;
Multiple daily ijnection using Insulin Degludec and Insulin Aspart: Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
        </group>
        <group group_id="E2">
          <title>Investigational Transition</title>
          <description>Administration of insulin degludec in 1:1 ratio (same units as total basal insulin on pump) on the day of randomization AND concomitant use of the insulin pump for 48 hours from transition, where insulin pump basal rate will be reduced by 50% during the first 24 hours from transition and by 75% during 24 to 48 hours from transition. Insulin pump will be disconnected after 48 hours from transition&#xD;
Multiple daily ijnection using Insulin Degludec and Insulin Aspart: Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>AE unrelated to the study</sub_title>
                <description>Common cold</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Single Center study with small sample size</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Viral Shah, Principal Investigator</name_or_title>
      <organization>University of Colorado Anschutz Medical Campus</organization>
      <phone>303-724-8186</phone>
      <email>viral.shah@cuanschutz.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

